Gliatech Histamine Antagonist Shows Positive Phase I Results
Dow Jones Newswires -- March 1, 1999
CLEVELAND --Gliatech said data from a Phase I rising single-
dose clinical study of its GT2331 histamine H3 antagonist, for the
potential treatment of Alzheimer's, Attention Deficit Hyperactivity
Disorder and sleep disorders, demonstrated positive results.
In a press release Monday, the therapeutic products maker said
the Phase I study of GT2331 was a double-blind, randomized,
placebo-controlled trial designed to investigate the safety,
tolerability and pharmacokinetic profile of GT2331 in healthy
volunteers.
Gliatech said several doses of GT2331 or placebo were administered,
and said no serious adverse events occurred at the doses evaluated,
with no clinically significant blood chemistry or hematological
differences in treated and controlled patients.
The company said pharmacokinetic analysis indicated GT2331 blood
levels higher than those expected for pharmacological effect, and
said GT2331 exhibited a plasma half-life which should allow for
once-daily dosing.
Gliatech said based on the favorable Phase I results, the company
initiated a rising multiple dose study, in which several doses of
GT2331 will be administered for two weeks to healthy volunteers.
(Richard H - So far so good!) Peter
|
